Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer

NCT06856499 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Endometrioid Ovarian Cancer
Primary Peritoneal Cancer
Fallopian Tube Cancer

Interventions

DRUG: Cirtuvivint
DRUG: Olaparib

Sponsor

University of Colorado, Denver

Collaborators

[object Object]
[object Object]